Status:
WITHDRAWN
SSRI's and the Rate of Progression From MCI to Dementia
Lead Sponsor:
Ohio State University
Conditions:
Mild Cognitive Impairment
Dementia
Eligibility:
All Genders
50+ years
Brief Summary
This trial is investigating if serotonin reuptake inhibitor (SSRI) use in Mild Cognitive Impairment (MCI) patients will lead to a lower rate of progression to dementia. It's hypothesized that patient...
Detailed Description
Whether SSRIs affect the progression of MCI to dementia is not well studied with longitudinal prospectively collected date. Any decrease in the incidence of the progression of MCI to Alzheimer's demen...
Eligibility Criteria
Inclusion
- Age 55+
- Diagnosis of mild cognitive impairment.
- One year treatment with an SSRI prior to diagnosis of MCI or six months treatment after diagnosis of MCI for the intervention groups. No treatment with an SSRI prior to the diagnosis of MCI or after the diagnosis of MCI for the control group.
- A minimum of two annual follow up evaluations.
Exclusion
- Patients with CNS infection or inflammation
- HIV
- Syphilis
- Patients with poorly controlled Epilepsy based on the opinion of the investigator.
- Patients with space occupying lesions of the brain (glioma, meningioma, brain metastasis).
- Patients with systemic inflammatory condition or cancer undergoing chemotherapy or on chronic immune modulatory treatments.
- Blind patients that were not able to complete a cognitive assessment.
- Patients with chronic pain who are on excluded pain medications.
- Patients with Attention Deficit Disorder that require the use of stimulant medications.
- Patients with Traumatic Brain Injury.
- Patients with Cerebral Aneurysm Rupture.
- Patients with chronic psychiatric conditions, unless in remission. Recurrent chronic psychiatric condition in relapse, chronic recurrent Major Depression in relapse, chronic recurrent bipolar disorder, chronic relapsing schizoaffective disorder and chronic recurrent anxiety disorder requiring chronic use of benzodiazepines are exclusionary.
- Patients taking an excluded medication.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 6 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04901494
Start Date
September 1 2021
End Date
October 6 2023
Last Update
October 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University
Columbus, Ohio, United States, 43221